Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1304-1310

  Boissinot, Marjorie ^a   Inman, Martyn ^b   Hempshall, Aiden ^b   James, Sally R ^a   Gill, Jason H ^c   Selby, Peter ^a   Bowen, David T ^d   Grigg, Ronald ^b   Cockerill, Peter N ^a,e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

AML; Apoptosis ; Benzamide; Differentiation; HDAC inhibitor; MI 192

Indexed keywords

BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; MI 192; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRAIN KASUMI 1; CELL STRAIN U937; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PURIFICATION; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

APOPTOSIS; BENZAMIDES; CELL DIFFERENTIATION; CELL PROLIFERATION; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA; TUMOR CELLS, CULTURED;

EID: 84865191332     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.002     Document Type: Article

References (31)

1. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
2. Karagianni P., Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007, 26:5439-5449.
3. Li P., Wang D., Yao H., Doret P., Hao G., Shen Q., et al. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 2010, 29:3153-3162.
4. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005, 15:490-495.
5. Liu S., Shen T., Huynh L., Klisovic M.I., Rush L.J., Ford J.L., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005, 65:1277-1284.
6. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008, 30:61-72.
7. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001, 21:6470-6483.
8. Peterson L.F., Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23:4255-4262.
9. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
10. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
11. Braiteh F., Soriano A.O., Garcia-Manero G., Hong D., Johnson M.M., Silva Lde P., et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008, 14:6296-6301.
12. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005, 40:1-13.
13. Itoh Y., Suzuki T., Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008, 14:529-544.
14. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008, 409:581-589.
15. Gozzini A., Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol 2005, 84(Suppl 1):54-60.
16. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010.
17. Yoshida M., Matsuyama A., Komatsu Y., Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 2003, 10:2351-2358.
18. Meinke P.T., Liberator P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr Med Chem 2001, 8:211-235.
19. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
20. Chou C.J., Herman D., Gottesfeld J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008, 283:35402-35409.
21. Duque-Afonso J., Yalcin A., Berg T., Abdelkarim M., Heidenreich O., Lubbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 2011, 30:3062-3072.
22. Nishioka C., Ikezoe T., Yang J., Takeuchi S., Koeffler H.P., Yokoyama A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008, 32:1382-1392.
23. Zhou N., Moradei O., Raeppel S., Leit S., Frechette S., Gaudette F., et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008, 51:4072-4075.
24. Moreno D.A., Scrideli C.A., Cortez M.A., de Paula Queiroz R., Valera E.T., da Silva Silveira V., et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010, 150:665-673.
25. Atsumi A., Tomita A., Kiyoi H., Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 2006, 345:1471-1480.
26. Gupta M., Han J.J., Stenson M., Wellik L., Witzig T.E. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2011.
27. Zhang X., Chen X., Lin J., Lwin T., Wright G., Moscinski L.C., et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2011.
28. Gillespie J., Savic S., Wong C., Hempshall A., Inman M., Emery P., et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012, 64:418-422.
29. Grigg R., Inman M., Kilner C., Koppen I., Marchbank J., Selby P., et al. Synthesis of carbo- and heterocycles via palladium catalysed cascade allene insertion-nucleophile incorporation-Michael addition processes. Tetrahedron 2007, 63:6152-6169.
30. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006, 6:813-823.
31. Jasek E., Mirecka J., Litwin J.A. Effect of differentiating agents (all-trans retinoic acid and phorbol 12-myristate 13-acetate) on drug sensitivity of HL60 and NB4 cells in vitro. Folia Histochem Cytobiol 2008, 46:323-330.